Compound: osimertinib
SMILES: O=C(Nc1c(N(CCN(C)C)C)cc(OC)c(c1)Nc2nc(-c3c4c(cccc4)n(c3)C)ccn2)C=C
InChIKey: DUYJMQONPNNFPI-UHFFFAOYSA-N
Synonyms: osimertinib, 1421373-65-0, AZD-9291, AZD9291, Mereletinib, AZD 9291, osimertinibum, N-(2-{[2-(Dimethylamino)ethyl](Methyl)amino}-4-Methoxy-5-{[4-(1-Methyl-1h-Indol-3-Yl)pyrimidin-2-Yl]amino}phenyl)prop-2-Enamide, 3C06JJ0Z2O, AZD-9291 FREE BASE, N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide, N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide, CHEBI:90943, DTXSID501025961, 2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-, N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)prop-2-enamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide, N-(2-(2-(dimethylamino)ethyl-methylamino)-4-methoxy-5-((4-(1-methylindol-3-yl)pyrimidin-2-yl)amino)phenyl)prop-2-enamide, RefChem:58257, L01XE35, DTXCID401510212, Osimertinib [USAN], N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide, UNII-3C06JJ0Z2O, MFCD27988062, C28H33N7O2, Osimertinib (AZD9291), AZD 9291(Osimertinib), Mereletinib [INN], 2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-; N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide; AZD 9291; Osimertinib; Tagrisso, N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)acrylamide, Osimertinib (Standard), OSIMERTINIB [MI], OSIMERTINIB [INN], Osimertinib; AZD 9291, Osimertinib; AZD-9291, mereletinib (obsolete INN), AZD 9291 (Osimertinib), AZD-9291(Osimertinib)?, OSIMERTINIB [WHO-DD], GTPL7719, orb1305406, orb3141352, CHEMBL3353410, SCHEMBL14660911, SCHEMBL29350904, SCHEMBL29378405, EX-A314, MereletinibAZD-9291,Osimertinib, DUYJMQONPNNFPI-UHFFFAOYSA-N, GLXC-05459, HMS3653E10, HMS3672M05, HMS5085F14, MSK11040, NQC28144, TVB02091, BDBM50029668, EBC-07876, HY-15772R, NSC779217, NSC781254, NSC800812, s7297, AKOS025290756, CCG-264683, CS-2018, DB09330, FD58317, NSC-779217, NSC-781254, NSC-800812, SB22952, NCGC00378622-03, NCGC00378622-04, NCGC00378622-10, AC-29019, AS-16943, BP-43647, HY-15772, 4714B, NS00073136, SW219863-1, EN300-7382438, BRD-K42805893-001-04-9, Q21506464, 2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-, AZD 9291, Osimertinib, Tagrisso, N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide, N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide, N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide, N-(2-{2-Dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide, N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4- (1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide, N-[2-[2-(dimethylamino)ethyl-methyl-amino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide
Theoretical properties:
molecular_formula: C28H33N7O2
molecular_weight: 499.6 g/mol
exact_mass: 499.26957332 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 7
rotatable_bond_count: 10
heavy_atom_count: 37
topological_polar_surface_area: 87.6 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Osimertinib is a member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer. It has a role as an antineoplastic agent and an epidermal growth factor receptor antagonist. It is a secondary carboxamide, a member of acrylamides, a member of indoles, a monomethoxybenzene, an aminopyrimidine, a substituted aniline, a secondary amino compound, a tertiary amino compound and a biaryl. It is a conjugate base of an osimertinib(1+).
chebi: A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer.
chembl: OSIMERTINIB is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor  tyrosine kinase inhibitor.
The most common side effects include diarrhea, rash, musculoskeletal pain, dry skin, skin inflammation around nails, sore mouth, fatigue, and cough.
Osimertinib was approved for medical use in the United States in November 2015, and in the European Union in February 2016.